Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

29. November 2011 09:00 ET | Quelle: Talon Therapeutics, Inc.

Talon Therapeutics Announces First Patient Enrolled in the Phase 3 OPTIMAL>60 Study of Marqibo(R) in Adult Patients With Newly Diagnosed, Aggressive Non-Hodgkin's Lymphoma

Conducted by the prestigious German High-Grade NHL Study Group R-CHMP-14 (M=Marqibo) versus R-CHOP-14 (O=standard vincristine) Powered to demonstrate superior progression-free survival of...
14. November 2011 17:00 ET | Quelle: Talon Therapeutics, Inc.

Talon Therapeutics, Inc. Reports Third Quarter 2011 Financial Results

SAN MATEO, Calif., Nov. 14, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc., (OTCBB:TLON), today reported financial results for the three and nine months ended September 30, 2011. "In the third...
11. November 2011 16:21 ET | Quelle: Talon Therapeutics, Inc.

Talon Therapeutics to Host a Conference Call to Report Third Quarter 2011 Financial Results and Business Update on November 15, 2011

SAN MATEO, Calif., Nov. 11, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) will host a conference call on Tuesday, November 15, 2011 at 9:00AM PT, to include a discussion of financial...
27. September 2011 09:00 ET | Quelle: Talon Therapeutics, Inc.

Talon Therapeutics' New Drug Application for Marqibo(R) Accepted for Filing by the United States Food and Drug Administration

Accelerated approval review path confirmed by the FDA Prescription Drug User Fee Act (PDUFA) date set for May 13, 2012 SAN MATEO, Calif., Sept. 27, 2011 (GLOBE NEWSWIRE) -- Talon...
29. August 2011 09:00 ET | Quelle: Talon Therapeutics, Inc.

Talon Therapeutics Receives Special Protocol Assessment Agreement from the Food and Drug Administration for Its Phase 3 Confirmatory Study of Marqibo(R) in Newly Diagnosed Acute Lymphoblastic Leukemia

SAN MATEO, Calif., Aug. 29, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc., (OTCBB:TLON), announced today the company has reached agreement with the U. S. Food and Drug Administration (FDA)...
15. August 2011 09:00 ET | Quelle: Talon Therapeutics, Inc.

Talon Therapeutics, Inc. Reports Second Quarter 2011 Financial Results

SAN MATEO, Calif., Aug. 15, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc., (OTCBB:TLON), today reported financial results for the three and six months ended June 30, 2011. "Submitting our new...
09. August 2011 09:00 ET | Quelle: Talon Therapeutics, Inc.

Talon Therapeutics to Host a Conference Call to Report Second Quarter 2011 Financial Results and Business Update on August 15, 2011

SAN MATEO, Calif., Aug. 9, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) will host a conference call on Monday, August 15, 2011 at 8:30AM PT, to include a discussion of results and...
20. Juli 2011 09:00 ET | Quelle: Talon Therapeutics, Inc.

Talon Therapeutics Announces First Patient Enrolled in National Cancer Institute Phase 1 Trial of Marqibo(R) in Children and Adolescents

SAN MATEO, Calif., July 20, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) today announced the enrollment of the first patient in a Phase 1 trial to evaluate the safety, activity and...
18. Juli 2011 09:00 ET | Quelle: Talon Therapeutics, Inc.

Talon Therapeutics Submits New Drug Application for Marqibo(R)

SAN MATEO, Calif., July 18, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) today announced its New Drug Application (NDA) for Marqibo (vincristine sulfate liposomes injection) was...
30. Juni 2011 09:00 ET | Quelle: Talon Therapeutics, Inc.

Talon Therapeutics Provides NDA Submission Timeline Update for Marqibo(R)

SAN MATEO, Calif., June 30, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) today provided an update of the status of its planned NDA submission for Marqibo ((vincristine sulfate...

Vorherige Seite